Dianthus Therapeutics, Inc.

Contributing Author

Recent Articles by Dianthus Therapeutics, Inc.

May-05	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results DNTH GlobeNewswire
May-01	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DNTH GlobeNewswire
Apr-06	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DNTH GlobeNewswire
Mar-12	Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares DNTH -6.43% GlobeNewswire
Mar-10	Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering DNTH GlobeNewswire
Mar-09	Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering DNTH +21.52% GlobeNewswire
Mar-09	Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results DNTH +21.52% GlobeNewswire
Mar-09	Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) DNTH +21.52% GlobeNewswire
Mar-08	Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) DNTH GlobeNewswire
Mar-03	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DNTH +11.99% DNTH GlobeNewswire
Feb-24	Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference DNTH GlobeNewswire
Feb-05	Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 DNTH GlobeNewswire
Jan-05	Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference DNTH -7.03% GlobeNewswire
Dec-23	Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) DNTH GlobeNewswire
Nov-24	Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference DNTH +5.38% GlobeNewswire
Nov-05	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results DNTH +8.00% DNTH GlobeNewswire
Nov-04	Dianthus Therapeutics to Participate in Four Investor Conferences During November DNTH GlobeNewswire
Oct-29	Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting DNTH GlobeNewswire
Oct-16	Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases DNTH GlobeNewswire
Oct-02	Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting DNTH -5.14% GlobeNewswire
Sep-11	Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares DNTH GlobeNewswire
Sep-09	Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering DNTH +6.55% GlobeNewswire
Sep-08	Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering DNTH +20.00% GlobeNewswire
Sep-08	Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile DNTH +20.00% GlobeNewswire
Sep-07	Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis DNTH GlobeNewswire
Aug-07	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results DNTH -6.08% GlobeNewswire
May-29	Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference DNTH GlobeNewswire
May-22	Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors DNTH GlobeNewswire
May-12	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results DNTH -6.18% DNTH GlobeNewswire
May-05	Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September DNTH GlobeNewswire

Dianthus Therapeutics, Inc.

Recent Articles by Dianthus Therapeutics, Inc.

Upgrade your Finviz experience